Title | Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. |
Publication Type | Journal Article |
Year of Publication | 2016 |
Authors | Mehra R, Udager AM, Ahearn TU, Cao X, Feng FY, Loda M, Petimar JS, Kantoff P, Mucci LA, Chinnaiyan AM |
Journal | Eur Urol |
Volume | 70 |
Issue | 4 |
Pagination | 549-552 |
Date Published | 2016 10 |
ISSN | 1873-7560 |
Keywords | Aged, Biomarkers, Tumor, Bone Neoplasms, Humans, In Situ Hybridization, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Prostatectomy, Prostatic Neoplasms, PTEN Phosphohydrolase, RNA, Long Noncoding, Survival Rate |
Abstract | The long noncoding RNA SChLAP1 is overexpressed in a subset of prostate cancers (PCa), and high SChLAP1 expression by in situ hybridization (ISH) independently predicts biochemical recurrence after radical prostatectomy. Importantly, although biochemical recurrence is a significant clinical outcome, it is not a validated surrogate for PCa-related mortality. Thus, we evaluated the association between SChLAP1 expression and development of lethal PCa in a large cohort of American men with PCa and long-term follow-up. SChLAP1 ISH was performed on tissue microarrays containing representative formalin-fixed, paraffin-embedded PCa tissue from all patients and scored using a semiquantitative method (ISH score range 0-400). Hazard ratios (HRs) for the association between SChLAP1 expression and time to development of lethal PCa were estimated using multivariable Cox regression analysis. Of the 937 patients evaluated, 89 (9.5%) had high SChLAP1 expression (ISH score ≥100), which in patients treated with radical prostatectomy was strongly associated with development of lethal PCa independent of age, Gleason score, pathologic stage, and PTEN status (HR 2.2, 95% confidence interval 1.1-4.1). These results suggest that SChLAP1 may be a useful tissue-based biomarker for identifying PCa patients at higher risk of lethal progression. PATIENT SUMMARY: We examined expression of the RNA molecule SChLAP1 in a large group of prostate cancer patients with long-term follow-up and found that patients with high SChLAP1 expression had a significantly higher chance of developing lethal disease. |
DOI | 10.1016/j.eururo.2015.12.003 |
Alternate Journal | Eur Urol |
PubMed ID | 26724257 |
PubMed Central ID | PMC4919276 |
Grant List | P50 CA090381 / CA / NCI NIH HHS / United States P01 CA055075 / CA / NCI NIH HHS / United States P30 CA008748 / CA / NCI NIH HHS / United States R01 CA133891 / CA / NCI NIH HHS / United States U01 CA113913 / CA / NCI NIH HHS / United States UM1 CA167552 / CA / NCI NIH HHS / United States P50 CA186786 / CA / NCI NIH HHS / United States P50 CA069568 / CA / NCI NIH HHS / United States R01 CA141298 / CA / NCI NIH HHS / United States |
Related Faculty:
Massimo Loda, M.D.